# EndoStim

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endostim

- Industry: Medical Devices & Equipment
- Headquarters: Dallas, US
- Website: www.endostim.com
- Total disclosed funding: $36M
- Latest round: Series D (Mar 10, 2016)
- Investors on record: 10

## About

EndoStim, Inc. specializes in developing innovative neurostimulation therapies for patients suffering from drug-refractory gastroesophageal reflux disease (GERD), aiming to improve their health and quality of life.EndoStim, Inc. is dedicated to addressing GERD through its pioneering EndoStim System, which employs neurostimulation to treat the condition. The company is headquartered in Dallas, US. Founded by Virender Sharma, the firm has seen strategic pivots throughout its development. It has engaged in 11 deals, with the latest funding round being VENTURE DEBT, raising USD 2.81 mn and bringing the total funds raised to USD 12.15 mn. The current CEO is Eric Goorno.EndoStim focuses on the EndoStim System, a neurostimulation treatment designed to deliver mild electrical signals to strengthen the lower esophageal sphincter (LES) in GERD patients. This innovative treatment strategy aims to provide lasting relief from reflux symptoms, primarily targeting patients in North America and Europe. The primary customers include healthcare providers, gastroenterologists, and hospitals that facilitate this treatment, addressing chronic pain and discomfort for patients.EndoStim generates revenue through the direct sale of its neurostimulation devices, specifically the EndoStim System, to healthcare institutions. Sales are facilitated through negotiated pricing agreements based on the volume of products ordered, involving one-time costs for the devices and potential ongoing service agreements for support and maintenance. This transaction structure plays a critical role in the company's revenue model.EndoStim, Inc. ceased its operations due to lack of funding.

## Funding rounds

- Series D, Mar 10, 2016, $11M — Wellington Partners, Gimv, Endeavour Vision, Sante Ventures
- Series C, May 29, 2013, $1.3M — BPEA Private Equity, Prolog Ventures, Sante Ventures, Stifel, Nicolaus & Co., Missouri Technology Corporation, St. Louis Arch Angels, Voyent Partners
- Series C, Apr 23, 2013, $1.5M — Sante Ventures
- Series C, Mar 19, 2013, $2.1M — Prolog Ventures, Sante Ventures
- Series C, Dec 5, 2012, $8.2M — Prolog Ventures, Sante Ventures
- Series C, Nov 22, 2011, $5.5M — Sante Ventures
- Series B, Jul 13, 2010, $6M — BPEA Private Equity, Prolog Ventures, Sante Ventures, Stifel, Nicolaus & Co.

## Investors

- BPEA Private Equity (https://capitalatlas.ai/funds/bpea-private-equity) — Series B, Series C
- Prolog Ventures (https://capitalatlas.ai/funds/prolog-ventures) — Series B, Series C
- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series B, Series C, Series D
- Stifel, Nicolaus & Co. — Series B, Series C
- Missouri Technology Corporation — Series C
- St. Louis Arch Angels — Series C
- Voyent Partners (https://capitalatlas.ai/funds/voyent-partners) — Series C
- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series D
- Gimv (https://capitalatlas.ai/funds/gimv) — Series D
- Endeavour Vision (https://capitalatlas.ai/funds/endeavour-vision) — Series D